The FDA submission is backed by robust data from the VALID-ECG pivotal study, which enrolled 198 patients across five clinical sites. The Company believes the study's findings support the clinical ...

Obesity significantly impacts cardiovascular health, increasing risks such as left ventricular hypertrophy, atherosclerosis, ...

Ncardia, a leading human induced pluripotent stem cell (hiPSC) technology company, today announced the launch of Ncyte® Heart ...

Most children with multisystem inflammatory syndrome in children recover quickly, according to study findings.

BioVentrix, Inc. Brings Extensive Leadership Experience to Senior Management Team Steve brings strong executive management & clinic ...

Following allocation system changes in 2018, heart transplant waitlist mortality decreased in patients with LVADs.

with the three-tier status system being expanded to a six-tier system. Patients with durable left ventricular assist devices were deprioritized and patients with acute mechanical circulatory ...

The anticipated product offering will complement our emphasis on the ventricular therapeutic market and expectation for continuing growth ... pericardial space of the heart and that it is intended ...